Current Ophthalmology Reports

, Volume 4, Issue 1, pp 30–37 | Cite as

Uveitic Macular Edema: Treatment Update

  • Raquel GoldhardtEmail author
  • Bradley Simon Rosen
Therapies in Age-Related Macular Degeneration (R. Goldhardt,Section Editor)
Part of the following topical collections:
  1. Therapies in Age-Related Macular Degeneration


The aim of this review is to summarize recent developments in the treatment of uveitic macular edema (ME). ME represent a major cause of visual loss in uveitis and adequate management is crucial for the maintenance of useful vision in patients with chronic uveitis.


Uveitic macular edema Uveitis Corticosteroids Immunosuppressive therapy Inflammation Inflammatory edema 



Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. 1.
    Jabs DA. Epidemiology of uveitis. Ophthal Epidemiol. 2008;15:283–4.CrossRefGoogle Scholar
  2. 2.
    • Ossewaarde-van Norel A, Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocular Immunol Inflamm. 2011;19:75–83. They propose an algorithm for the treatment of uveitic macular edema pointing out the individual risk-benefit ratio when systemic immunosuppressive therapy is used.Google Scholar
  3. 3.
    Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574–9 e1.Google Scholar
  4. 4.
    •• Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11:29–38. Highlights the current understanding of pathophysiology and immunology of uveitic macular edema.Google Scholar
  5. 5.
    Dick AD. The treatment of chronic uveitic macular oedema. Br J Ophthalmol. 1994;78:1–2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rothova A. Medical treatment of cystoid macular edema. Ocular Immunol Inflamm. 2002;10:239–46.CrossRefGoogle Scholar
  7. 7.
    Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22:1133–40.CrossRefPubMedGoogle Scholar
  8. 8.
    van Haeringen NJ, van Sorge AA, Core-Bodelier VMC. Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J Ocul Pharmacol. 2000;16:353–61.CrossRefGoogle Scholar
  9. 9.
    Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005;140:1096–105.CrossRefPubMedGoogle Scholar
  10. 10.
    •• van Kooij B, Probst K, Fijnheer R, Roest M, de Loos W, Rothova A. Risk factors for cystoid macular oedema in patients with uveitis. Eye (Lond). 2008;22:256–60. Retrospective cross-sectional study evaluating ophthalmologic and systemic factors associated with uveitic macular edema.Google Scholar
  11. 11.
    Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145:841–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    • Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113:1446–9. Cross-sectional study that investigated causes of decrease in visual acuity in patients with uveitis.Google Scholar
  13. 13.
    de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30:260–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10:2379–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010;88:896–900.CrossRefPubMedGoogle Scholar
  17. 17.
    Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology. 2011;118:2120–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147–54.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:1801–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Angunawela RI, Heatley CJ, Williamson TH, et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand. 2005;83:595–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16:217–23.CrossRefPubMedGoogle Scholar
  23. 23.
    Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(441–8):e2.PubMedGoogle Scholar
  24. 24.
    Jea SY, Byon IS, Oum BS. Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis. Korean J Ophthalmol. 2006;20:99–103.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;25:159–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–49.CrossRefPubMedGoogle Scholar
  27. 27.
    Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116:455–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114:1912–8.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118:1916–26. Randomized controlled parallel superiority trial comparing systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis by MUST.Google Scholar
  30. 30.
    Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41:3569–75.PubMedGoogle Scholar
  31. 31.
    Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126:1191–201.CrossRefPubMedGoogle Scholar
  32. 32.
    Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567–75, 75 e1.Google Scholar
  33. 33.
    Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–7.CrossRefPubMedGoogle Scholar
  35. 35.
    London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28:351–66.CrossRefPubMedGoogle Scholar
  36. 36.
    Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53.CrossRefPubMedGoogle Scholar
  37. 37.
    • Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309–17. This was a 6-month randomized study using a single dexamethasone DDS treatment in patients with persistent macular edema. Google Scholar
  38. 38.
    Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29:501–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Venkatesh P, Abhas Z, Garg S, Vohra R. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Archive Clin Exp Ophthal. 2007;245:59–67.CrossRefGoogle Scholar
  40. 40.
    •• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492–513. Recommendations of a 12-person panel of physicians with expertise in ophthalmic, pediatric and rheumatologic disease for the use of immunosuppressive therapy in patient care. Google Scholar
  41. 41.
    •• Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996;103:1054–62; discussion 62–3. This was a randomized cross-over trial including 37 patients comparing acetazolamide versus placebo. They received a 4-week course of either acetazolamide or placebo followed by a 4-week washout period.Google Scholar
  42. 42.
    Farber MD, Lam S, Tessler HH, Jennings TJ, Cross A, Rusin MM. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol. 1994;78:4–7.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Lashay AR, Rahimi A, Chams H, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease. Eye (Lond). 2003;17:762–6.CrossRefGoogle Scholar
  44. 44.
    Kafkala C, Choi JY, Choopong P, Foster CS. Octreotide as a treatment for uveitic cystoid macular edema. Arch Ophthalmol. 2006;124:1353–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Missotten T, van Laar JA, van der Loos TL, et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol. 2007;144:838–43.CrossRefPubMedGoogle Scholar
  46. 46.
    Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14:285–94.PubMedGoogle Scholar
  47. 47.
    Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007;12:443–50.CrossRefPubMedGoogle Scholar
  48. 48.
    Karim R, Tang B. Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol. 2010;4:493–517.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003;112:1655–65.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    • Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 2009;23:1812–8. In one group they measured intravitreal VEGF levels in uveitis patients and controls and in a second group they treated macular edema with anti-VEGF. If no response, they switched to triamcinolone. VEGF levels in uveitic patients were similar to patients with AMD. Anti-VEGF had a positive effect in uveitic macular edema when there wasn’t an extensive breakdown of the outer blood-retinal barrier or extensive leakage.Google Scholar
  51. 51.
    Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol. 2009;19:622–9.PubMedGoogle Scholar
  52. 52.
    Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Al-Dhibi H, Hamade IH, Al-Halafi A, et al. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema. J Ophthalmol. 2014;2014:729465.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Okada AA, Keino H, Watanabe T, Taki W, Hayakawa R. Recurrence of acute anterior inflammation after intravitreal injection of bevacizumab in uveitis. Jpn J Ophthalmol. 2009;53:182–4.CrossRefPubMedGoogle Scholar
  55. 55.
    Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–9.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29:313–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Goldberg RA, Shah CP, Wiegand TW, Heier JS. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol. 2014;158(733–7):e1.CrossRefPubMedGoogle Scholar
  58. 58.
    Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117:1612–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004;49:470–90.CrossRefPubMedGoogle Scholar
  60. 60.
    Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–50.CrossRefPubMedGoogle Scholar
  61. 61.
    Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol. 2009;29:127–33.CrossRefPubMedGoogle Scholar
  62. 62.
    Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol. 2009;3:559–66.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–91.CrossRefPubMedGoogle Scholar
  65. 65.
    Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61.CrossRefPubMedGoogle Scholar
  66. 66.
    Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–13.CrossRefPubMedGoogle Scholar
  67. 67.
    Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17:403–14.CrossRefPubMedGoogle Scholar
  68. 68.
    Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–61.CrossRefPubMedGoogle Scholar
  69. 69.
    Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116:797–801.CrossRefPubMedGoogle Scholar
  70. 70.
    Wang J, Ibrahim M, Turkcuoglu P, et al. Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul Immunol Inflamm. 2010;18:395–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Nussenblatt RB, Kim J, Thompson DJ, et al. Vitamin E in the treatment of uveitis-associated macular edema. Am J Ophthalmol. 2006;141:193–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Suttorp-Schulten MS, Feron E, Postema F, Kijlstra A, Rothova A. Macular grid laser photocoagulation in uveitis. Br J Ophthalmol. 1995;79:821–4.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm. 2007;15:71–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Gutfleisch M, Spital G, Mingels A, Pauleikhoff D, Lommatzsch A, Heiligenhaus A. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol. 2007;91:345–8.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Schaal S, Tezel TH, Kaplan HJ. Surgical intervention in refractory CME—role of posterior hyaloid separation and internal limiting membrane peeling. Ocul Immunol Inflamm. 2008;16:209–10.CrossRefPubMedGoogle Scholar
  76. 76.
    Garweg JG, Becker M, Lommatzsch A, Bartz-Schmidt KU. Update on vitrectomy for pediatric uveitis. Klin Monbl Augenheilkd. 2007;224:538–42.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media New York 2016

Authors and Affiliations

  1. 1.Clinical Ophthalmology, Bascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Los AngelesUSA

Personalised recommendations